US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

Index Rebalance professional of US, EU and Global Indices. Specialized in shareholder structure and index free float calculation, SPACs, quarterly rebalance predictions of US-EU indices and cross-index implications of corporate actions such as M&A's, Spin-offs and IPOs.

All forecasts and calculations are estimates derived from a combination of public sources considered reliable. These sources include, but are not limited to, exchange and regulatory filings, company announcements, and ETFs. While best efforts are made to maximize accuracy, estimates and predictions are subject to uncertainty.

No index data are used.

US-EU Index Rebalances / Quantitative Researcher

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/galderma-group-ag" target="_blank" data-smartkarma-citation="entities:43861:1" rel="noopener">Galderma (GALD SW)</a> is one of the largest Global and Swiss Index additions at the August and September 2024 reviews following its recent IPO valued at ~$17bn.</li>
<li>The company is forecasted to get added in the second Global Index at the September 2024 review. Estimated demand is ~$162m and ~5.0 ADV.</li>
<li>The IPO lock-up expiry is forecasted to generate an additional demand of ~$42m and ~1.3 ADV at the December 2024 review. </li>
</ul>



Galderma (GALD SW) is one of the largest Global and Swiss Index additions at the August and September 2024 reviews following its recent IPO valued at ~$17bn.
The company is forecasted to get added in the second Global Index at the September 2024 review. Estimated demand is ~$162m and ~5.0 ADV.
The IPO lock-up expiry is forecasted to generate an additional demand of ~$42m and ~1.3 ADV at the December 2024 review. 


Galderma (GALD): Successful Injection in Swiss & Global Indices